Table 5 Distribution of screening examinations prior to interval cancer after To-Be 1 (n = 19) and resulting in consecutive round screen-detected cancer in To-Be 2 (n = 91) classified into false negative, minimal sign significant, minimal sign non-specific, and true negative in the informed consensus-based review, by mammographic density and histopathologic tumor characteristics
Screening examinations prior to interval cancer (n = 19) | Screening examinations resulting in consecutive round screen-detected cancer (n = 91) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
False negative | Minimal sign significant | Minimal sign non-specific | True negative | False negative | Minimal sign significant | Minimal sign non-specific | True negative | |||||||||
n | 1 | 2 | 2 | 14 | 17 | 14 | 14 | 46 | ||||||||
% | 5% | 11% | 11% | 74% | 19% | 15% | 15% | 51% | ||||||||
Mammographic density | ||||||||||||||||
a | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 3 | 21% | 2 | 4% |
b | 1 | 100% | 0 | 0% | 0 | 0% | 1 | 7% | 3 | 18% | 5 | 36% | 2 | 14% | 14 | 30% |
c | 0 | 0% | 2 | 100% | 2 | 100% | 8 | 57% | 13 | 76% | 4 | 29% | 6 | 43% | 22 | 48% |
d | 0 | 0% | 0 | 0% | 0 | 0% | 5 | 36% | 1 | 6% | 5 | 36% | 3 | 21% | 8 | 17% |
Mammographic feature | ||||||||||||||||
Mass | 0 | 0% | 0 | 0% | 1 | 50% | - | 3 | 18% | 4 | 29% | 2 | 14% | - | ||
Spiculated mass | 0 | 0% | 0 | 0% | 0 | 0% | - | 3 | 18% | 2 | 14% | 2 | 14% | - | ||
Asymmetry | 0 | 0% | 1 | 50% | 0 | 0% | - | 2 | 12% | 0 | 0% | 3 | 21% | - | ||
Architectural distortion | 0 | 0% | 0 | 0% | 1 | 50% | - | 6 | 35% | 4 | 29% | 3 | 21% | - | ||
Calcification | 0 | 0% | 0 | 0% | 0 | 0% | - | 1 | 6% | 2 | 14% | 4 | 29% | - | ||
Density with calcification | 1 | 100% | 1 | 50% | 0 | 0% | - | 2 | 12% | 2 | 14% | 0 | 0% | - | ||
Type | ||||||||||||||||
Ductal carcinoma in situ | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 2 | 12% | 2 | 14% | 5 | 36% | 5 | 11% |
Invasive | 1 | 100% | 2 | 100% | 2 | 100% | 14 | 100% | 15 | 88% | 12 | 86% | 9 | 64% | 41 | 89% |
No special type | 0 | 0% | 1 | 50% | 1 | 50% | 10 | 71% | 5 | 33% | 10 | 83% | 7 | 78% | 30 | 73% |
Lobular | 0 | 0% | 0 | 0% | 0 | 0% | 2 | 14% | 5 | 33% | 1 | 8% | 1 | 11% | 8 | 20% |
Tubular | 0 | 0% | 0 | 0% | 1 | 50% | 0 | 0% | 5 | 33% | 0 | 0% | 1 | 11% | 0 | 0% |
Other | 1 | 100% | 1 | 50% | 0 | 0% | 2 | 14% | 0 | 0% | 1 | 8% | 0 | 0% | 3 | 7% |
Tumor diameter | ||||||||||||||||
≤ 10 mm | 0 | - | 0 | 0% | 1 | 50% | 0 | 0% | 6 | 43% | 4 | 36% | 2 | 22% | 10 | 29% |
11–20 mm | 0 | - | 0 | 0% | 0 | 0% | 6 | 75% | 4 | 29% | 7 | 64% | 6 | 67% | 17 | 50% |
> 20 – ≤ 50 mm | 0 | - | 1 | 100% | 1 | 50% | 2 | 25% | 4 | 29% | 0 | 0% | 1 | 11% | 7 | 21% |
Missinga | 1 | 1 | 0 | 6 | 1 | 1 | 0 | 7 | ||||||||
Histologic grade | ||||||||||||||||
Grade 1 | 0 | - | 0 | 0% | 1 | 50% | 1 | 8% | 6 | 40% | 7 | 64% | 1 | 11% | 14 | 39% |
Grade 2 | 0 | - | 0 | 0% | 0 | 0% | 7 | 58% | 4 | 27% | 4 | 36% | 6 | 67% | 16 | 44% |
Grade 3 | 0 | - | 1 | 100% | 1 | 50% | 4 | 33% | 5 | 33% | 0 | 0% | 2 | 22% | 6 | 17% |
Missing | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 5 | ||||||||
Lymph node positive | 0 | 0% | 0 | 0% | 0 | 0% | 6 | 43% | 2 | 13% | 0 | 0% | 1 | 11% | 4 | 10% |
Subtype | ||||||||||||||||
Luminal A | 0 | 0% | 0 | 0% | 1 | 50% | 4 | 29% | 9 | 60% | 9 | 82% | 5 | 56% | 24 | 60% |
Luminal B HER2 − | 0 | 0% | 0 | 0% | 0 | 0% | 5 | 36% | 6 | 40% | 2 | 18% | 2 | 22% | 10 | 25% |
Luminal B HER2 + | 1 | 100% | 0 | 0% | 0 | 0% | 2 | 14% | 0 | 0% | 0 | 0% | 1 | 11% | 3 | 8% |
HER2 + | 0 | 0% | 1 | 50% | 0 | 0% | 1 | 7% | 0 | 0% | 0 | 0% | 1 | 11% | 1 | 3% |
Triple negative | 0 | 0% | 1 | 50% | 1 | 50% | 2 | 14% | 0 | 0% | 0 | 0% | 0 | 0% | 2 | 5% |
Missing | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | ||||||||